Abstract
This article reports a male mid-aged patient with a rare neuroendocrine tumor in hepatic hilum who finally received surgical treatment after multidisciplinary treatment (MDT). After the condition was confirmed, the patient received sandostatin treatment based on MDT consultations and his family's willingness due to the high surgical risk. One year later, follow-up examinations showed "stable disease" (SD), and sandostatin was withdrawn due to economic consideration. One year after drug withdrawal, liver metastases were found. Sutent treatment was then applied after a second MDT consultation. Four months later, further examinations showed a partial response (PR). Finally, the patient received surgical treatment in the department of surgery.